Ignite Creation Date:
2025-12-24 @ 5:09 PM
Ignite Modification Date:
2026-01-23 @ 6:55 AM
Study NCT ID:
NCT06841250
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2025-02-24
First Post:
2025-02-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Early Changes in OCT Biomarkers After the First Intravitreal Anti-VEGF Injection in Treatment-naïve DME
Sponsor:
Sohag University
Organization:
Study Overview
Official Title:
Early Changes in OCT Biomarkers After the First Intravitreal Anti-VEGF Injection in Treatment-naïve DME
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2025-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A retrospective, observational, hospital-based study which will be conducted in the Department of Ophthalmology, Sohag University Hospital, Egypt.
Detailed Description:
Aim of the work To evaluate early changes in OCT biomarkers and visual acuity in treatment-naïve patients with diabetic macular oedema after the first intravitreal antiVEGF injection.
Patients and methods Study Design A retrospective, observational, hospital-based study which will be conducted in the Department of Ophthalmology, Sohag University Hospital, Egypt.
Patients This study will include 50 eyes with center-involving DME (CI-DME) of patients who received their 1st AntiVEGF injection as a routine treatment in the Department of Ophthalmology, Sohag University Hospital.
Inclusion Criteria
1. Diabetic patients with center-involving DME (CI-DME) who are treatment-naïve.
2. Central macular thickness (CMT) of 300 microns or more will be accepted as CI-DME.
Exclusion Criteria
1. Media opacities affecting OCT imaging (corneal pathologies, dense cataracts, vitreous opacities, etc).
2. Patients with any other retinal vascular diseases (retinal vein occlusion, central serrous chorioretinopathy, age-related macular degeneration, etc).
3. Patients who have had previous intravitreal injections or Laser treatment.
4. Patients who underwent previous vitreoretinal surgeries.
5. Patients with recent history of undergoing cataract surgery.
6. Patients with uncontrolled glaucoma or ocular inflammations (eg: vitritis). 4
Methods
We will analyze the medical records of the study participants before and after injection and the collected data will include:
A. History:
Patient age, gender, duration and treatment of diabetes mellitus, visual impairment history, ocular/systemic comorbidities, topical/systemic drug intake, previous ocular/systemic interventional procedures or surgery.
B. Medical Examination and Laboratory investigations:
Blood Pressure, Lipid profile, HbA1c will be measured.
C. Full ophthalmological examination:
Data recorded from the preoperative ophthalmic examination of the studied eye, which includes:
1. Best corrected visual acuity (BCVA): Snellen visual acuities will be presented as Snellen decimal notation.
2. Intraocular pressure (IOP) measured by I-Care rebound tonometer.
3. Slit lamp examination of the anterior segment and angle of the anterior chamber.
4. Fundus examination by indirect ophthalmoscope and slit lamp biomicroscopy with documentation of the stage of diabetic retinopathy.
D. OCT imaging:
OCT images and data will be collected and analysed from the electronic medical reports for all patients at 3 points:
1. Before injection (within one week before the procedure).
2. Two weeks after injection.
3. One month after injection. 5
The collected OCT data will include the following biomarkers:
* Determining the type of DME (diffuse, cystoid, serous retinal detachment).
* Mean central subfield thickness (CST).
* Presence, location and height of macular Intraretinal cystoid spaces (ICS).
* Presence of Subfoveal neuroretinal detachment (SND) and height of serous macular detachment.
* The presence and size, and localization of hyperreflective foci (HF) within the retina.
* The disorganisation of the inner retinal layers (DRIL).
* The presence of vitreomacular traction.
* The integrity of the outer retinal layers, (ellipsoid zone (EZ) and external limiting membrane (ELM)).
E. Theinjectionprocedure:
The surgical notes will be reviewed from the patient's files to report the injection procedure, preparations and complications.
Patients and methods Study Design A retrospective, observational, hospital-based study which will be conducted in the Department of Ophthalmology, Sohag University Hospital, Egypt.
Patients This study will include 50 eyes with center-involving DME (CI-DME) of patients who received their 1st AntiVEGF injection as a routine treatment in the Department of Ophthalmology, Sohag University Hospital.
Inclusion Criteria
1. Diabetic patients with center-involving DME (CI-DME) who are treatment-naïve.
2. Central macular thickness (CMT) of 300 microns or more will be accepted as CI-DME.
Exclusion Criteria
1. Media opacities affecting OCT imaging (corneal pathologies, dense cataracts, vitreous opacities, etc).
2. Patients with any other retinal vascular diseases (retinal vein occlusion, central serrous chorioretinopathy, age-related macular degeneration, etc).
3. Patients who have had previous intravitreal injections or Laser treatment.
4. Patients who underwent previous vitreoretinal surgeries.
5. Patients with recent history of undergoing cataract surgery.
6. Patients with uncontrolled glaucoma or ocular inflammations (eg: vitritis). 4
Methods
We will analyze the medical records of the study participants before and after injection and the collected data will include:
A. History:
Patient age, gender, duration and treatment of diabetes mellitus, visual impairment history, ocular/systemic comorbidities, topical/systemic drug intake, previous ocular/systemic interventional procedures or surgery.
B. Medical Examination and Laboratory investigations:
Blood Pressure, Lipid profile, HbA1c will be measured.
C. Full ophthalmological examination:
Data recorded from the preoperative ophthalmic examination of the studied eye, which includes:
1. Best corrected visual acuity (BCVA): Snellen visual acuities will be presented as Snellen decimal notation.
2. Intraocular pressure (IOP) measured by I-Care rebound tonometer.
3. Slit lamp examination of the anterior segment and angle of the anterior chamber.
4. Fundus examination by indirect ophthalmoscope and slit lamp biomicroscopy with documentation of the stage of diabetic retinopathy.
D. OCT imaging:
OCT images and data will be collected and analysed from the electronic medical reports for all patients at 3 points:
1. Before injection (within one week before the procedure).
2. Two weeks after injection.
3. One month after injection. 5
The collected OCT data will include the following biomarkers:
* Determining the type of DME (diffuse, cystoid, serous retinal detachment).
* Mean central subfield thickness (CST).
* Presence, location and height of macular Intraretinal cystoid spaces (ICS).
* Presence of Subfoveal neuroretinal detachment (SND) and height of serous macular detachment.
* The presence and size, and localization of hyperreflective foci (HF) within the retina.
* The disorganisation of the inner retinal layers (DRIL).
* The presence of vitreomacular traction.
* The integrity of the outer retinal layers, (ellipsoid zone (EZ) and external limiting membrane (ELM)).
E. Theinjectionprocedure:
The surgical notes will be reviewed from the patient's files to report the injection procedure, preparations and complications.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?: